Elite Pharmaceuticals Inc (ELTP)

[richme]

Two of the features of the 5 involved the use of "Top-line data" to be released in the future. Although I read the previous posts on the board regarding top line the obvious escaped me. Top-line data does not signify at all that trials were successful, only that the best information from the study is available and presumably is under review. Which gets back to Elite and its use of top line. To me Elite is saying we have our top line data (or information that we were seeking) but we have not analyzed that data "and don't really know if the trials were successful."

Elite then goes a la no efficacy trials will be needed and throws a few suggestions indicative of success. It is up to the individual investor to believe or not to believe and it appears from the volume since the CC that most of investors are guarded in their approach to Elite as they probably should be.


5 Big FDA Decisions Expected in September

Xenoport Inc. (NASDAQ: XNPT) completed enrollment in its Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis and reiterated its plans to disclose top-line data from this trial by the end of the third quarter, meaning September. Xenoport shares were at $6.67 on Friday’s close. The consensus price target is $11.50, and the 52-week trading range is $4.85 to $9.60.

Apricus Biosciences Inc. (NASDAQ: APRI) enrolled its last patient in its RayVa Phase 2a proof-of-concept study, back in June. The top-line data from this study is expected to be released in the third quarter. At that time it will report safety and proof-of-concept data from its RayVa Phase 2a clinical trial in patients with Raynaud’s phenomenon secondary to scleroderma. Shares of Apricus closed most recently at $1.35, in a 52-week trading range of $0.92 to $2.75. The stock has a consensus price target of $4.63.



Read more: 5 Big FDA Decisions Expected in September - 24/7 Wall St. http://247wallst.com/healthcare-business/2015/08/29/5-big-fda-decisions-expected-in-september/#ixzz3kEKcnz4l
Follow us: @247wallst on Twitter | 247wallst on Facebook